

Abzyme and Ibex Expand Partnership for the Discovery of Antibodies

Royersford, PA, February 15, 2017 – Abzyme Therapeutics, a biopharmaceutical company developing novel therapeutic antibodies using Self-Diversifying Antibody Library Platform (SDALib), announces a collaborative agreement with Ibex Biosciences, LLC (Ibex), a privately held biotechnology company focused on treating and diagnosing cancer and other diseases. This collaboration in developing new antibodies is the extension of a previous successful Abzyme/Ibex partnership for developing VHH antibodies. The collaboration will leverage Abzyme's SDALib technology and Ibex's expertise in the development of therapeutics for treatment of cancers to generate single domain camelid antibodies which can specifically bind to cancer-related target isoforms. Using Abzyme's yeast-based camelid single domain VHH antibody library with self-diversifying ability, VHH antibodies against Ibex's proprietary targets will be developed. Due to their small size and unique structure, single domain camelid VHH antibodies are ideal for labeling/targeting studies and as building blocks for the generation of novel biological drugs with multiple advantages. Under the agreement, Ibex will make upfront payments to Abzyme. Abzyme will also receive research funding and is eligible for technical milestone payments. Ibex will retain worldwide commercial rights to these therapeutic products. Financial terms of the partnership were not disclosed.

It is our pleasure to work closely with Ibex, they have been a great partner "said Hiep Tran, Chief Executive Officer and Co-Founder of Abzyme". I am delighted to have Ibex's continuing trust in our technologies and our antibody development capacities. We look forward to continue our partner in developing many more antibody candidates and to move them forward into clinical trials.

For further information, please contact:

Abzyme Therapeutics LLC

Rolf K. Swoboda, PhD.

Director of Antibody Development and Production

Phone: 610-990-7531

E-mail: swoboda@abzymetx.com